Paclitaxel plus carboplatin (PC) combination treatment was considered a standard of care for women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, revealed results from the phase III NRG Oncology clinical trial GOG 0261.
The study concludes that among uterine cancer patients treatment with PC was not inferior to paclitaxel plus ifosfamide (PI) based on the primary objective overall survival (OS), and PC was associated with longer progression-free survival (PFS) outcomes when compared with PI. These results were recently presented at the American Society for Clinical Oncology (ASCO) Annual Meeting and was awarded a "Best of ASCO" designation.
"While they are rare, gynecologic carinosarcomas are extremely aggressive and there has been a great deal of debate surrounding what the ideal or optimal treatment regimen would be for the women who have these malignancies," stated Matthew A. Powell, MD, of the Washington University School of Medicine and the lead author of the NRG-GOG 0261 abstract. "Previous Phase 2 research suggested that paclitaxel combined with carboplatin may improve outcomes for this patient population in terms of safety and convenience of treatment, so we tested this against a treatment regimen that included paclitaxel and ifosfamide."
"The hope is to continue to improve survival and quality of life outcomes for women who experience this rare malignancy," added Dr. Powell.